Friedmund Bachmann
Vice President CMC & Project Lead OncoOne
Friedmund Bachmann is Vice President CMC & Project Lead at OncoOne, where he leads CMC strategy and cross-functional development of the proprietary PreTarg-it® platform toward clinical translation. He brings more than 25 years of pharmaceutical and biotechnology experience spanning preclinical development, late-stage development, regulatory approval, commercialization, and lifecycle management. During his career, he has steered complex late-stage programs through major development challenges, positioning them for continued progression across the product lifecycle, including BLA approval and commercialization. His expertise spans radiopharmaceuticals and diverse biologic modalities across oncology, hematology, and inflammatory diseases. Friedmund combines scientific depth, strategic leadership, and operational execution.
Seminars
- Navigating the transition from a completed preclinical package into first-in-human development, identifying the critical hurdles that emerge as novel theranostic programmes approach the clinic
- Coordinating clinical, CMC and regulatory requirements to build a cohesive translational strategy and avoid delays between preclinical completion and patient dosing
- Applying lessons learned from preparing an early-stage radiopharmaceutical programme for Phase I to anticipate translational challenges earlier and accelerate novel theranostics towards patients
- Examining how the pharmacokinetic coupling of tumor targeting and radionuclide delivery constrains the therapeutic window of conventional radiopharmaceuticals
- Exploring how pre-targeting separates tumor localization from radionuclide administration to improve tumor-to-non-tumor tissue exposure and enable more flexible radionuclide delivery
- Sharing lessons learned from candidate selection, platform optimization, and preclinical development in advancing next-generation pre-targeting technologies
- Identifying the target characteristics and disease settings most likely to benefit from pre-targeting and unlock previously inaccessible therapeutic opportunities
